Lymphoma, T-Cell, Cutaneous
"Lymphoma, T-Cell, Cutaneous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.
| Descriptor ID |
D016410
|
| MeSH Number(s) |
C04.557.386.480.750.800 C15.604.515.569.480.750.800 C20.683.515.761.480.750.800
|
| Concept/Terms |
Lymphoma, T-Cell, Cutaneous- Lymphoma, T-Cell, Cutaneous
- T-Cell Lymphoma, Cutaneous
- T Cell Lymphoma, Cutaneous
- Cutaneous T-Cell Lymphoma
- Cutaneous T Cell Lymphoma
- Cutaneous T-Cell Lymphomas
- Lymphoma, Cutaneous T-Cell
- Lymphomas, Cutaneous T-Cell
- T-Cell Lymphomas, Cutaneous
- Lymphoma, T Cell, Cutaneous
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, T-Cell, Cutaneous".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Lymphoma [C04.557.386]
- Lymphoma, Non-Hodgkin [C04.557.386.480]
- Lymphoma, T-Cell [C04.557.386.480.750]
- Lymphoma, T-Cell, Cutaneous [C04.557.386.480.750.800]
- Hemic and Lymphatic Diseases [C15]
- Lymphatic Diseases [C15.604]
- Lymphoproliferative Disorders [C15.604.515]
- Lymphoma [C15.604.515.569]
- Lymphoma, Non-Hodgkin [C15.604.515.569.480]
- Lymphoma, T-Cell [C15.604.515.569.480.750]
- Lymphoma, T-Cell, Cutaneous [C15.604.515.569.480.750.800]
- Immune System Diseases [C20]
- Immunoproliferative Disorders [C20.683]
- Lymphoproliferative Disorders [C20.683.515]
- Lymphoma [C20.683.515.761]
- Lymphoma, Non-Hodgkin [C20.683.515.761.480]
- Lymphoma, T-Cell [C20.683.515.761.480.750]
- Lymphoma, T-Cell, Cutaneous [C20.683.515.761.480.750.800]
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, T-Cell, Cutaneous".
This graph shows the total number of publications written about "Lymphoma, T-Cell, Cutaneous" by people in this website by year, and whether "Lymphoma, T-Cell, Cutaneous" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoma, T-Cell, Cutaneous" by people in Profiles.
-
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2022 09 01; 158(9):1031-1039.
-
Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: a retrospective single-centre case series. Br J Dermatol. 2022 01; 186(1):153-166.
-
Dupilumab and cutaneous T-cell lymphoma. J Am Acad Dermatol. 2020 07; 83(1):33-34.
-
The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis. J Dermatol Sci. 2018 Jun; 90(3):343-356.
-
Rapid deterioration in a patient with primary aggressive cutaneous epidermotropic CD8+ cytotoxic T-cell ('Berti') lymphoma after administration of adalimumab. J Am Acad Dermatol. 2014 Sep; 71(3):e86-7.
-
Eosinophils in mycosis fungoides: an uncommon finding in the patch and plaque stages. Am J Dermatopathol. 2012 Aug; 34(6):586-91.
-
Subcutaneous panniculitic T-cell lymphoma in children: response to combination therapy with cyclosporine and chemotherapy. J Am Acad Dermatol. 2004 Feb; 50(2 Suppl):S18-22.
-
Cutaneous T-cell lymphoma. J Eur Acad Dermatol Venereol. 2003 Mar; 17(2):131-7.
-
Therapeutic approaches in cutaneous lymphoma. Dermatol Clin. 1994 Apr; 12(2):433-41.